Operating Cash Flow CAGR:14.34%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, Operating Cash Flow CAGR averages 52.25% over 3 years and 17.60% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash ResMed Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
RMD Operating Cash Flow CAGR Chart
ResMed Inc. (RMD)
RMD Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
RMD Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $1.40B | $1.75B | +$350.33M | +25.00% | +25.00% |
| 2024 | $693.30M | $1.40B | +$707.96M | +102.11% | +102.11% |
| 2023 | $351.15M | $693.30M | +$342.15M | +97.44% | +97.44% |
| 2022 | $736.72M | $351.15M | $-385.57M | -52.34% | -52.34% |
| 2021 | $802.25M | $736.72M | $-65.54M | -8.17% | -8.17% |
| 2020 | $459.05M | $802.25M | +$343.20M | +74.76% | +74.76% |
| 2019 | $505.03M | $459.05M | $-45.98M | -9.10% | -9.10% |
| 2018 | $414.05M | $505.03M | +$90.97M | +21.97% | +21.97% |
| 2017 | $547.93M | $414.05M | $-133.88M | -24.43% | -24.43% |
| 2016 | $383.18M | $547.93M | +$164.75M | +43.00% | +43.00% |
| 2015 | $391.27M | $383.18M | $-8.09M | -2.07% | -2.07% |
| 2014 | $402.82M | $391.27M | $-11.55M | -2.87% | -2.87% |
| 2013 | $383.16M | $402.82M | +$19.66M | +5.13% | +5.13% |
| 2012 | $283.19M | $383.16M | +$99.97M | +35.30% | +35.30% |
| 2011 | $188.21M | $283.19M | +$94.98M | +50.46% | +50.46% |
| 2010 | $238.88M | $188.21M | $-50.66M | -21.21% | -21.21% |
| 2009 | $137.84M | $238.88M | +$101.04M | +73.31% | +73.31% |
| 2008 | $91.11M | $137.84M | +$46.73M | +51.29% | +51.29% |
| 2007 | $99.03M | $91.11M | $-7.92M | -8.00% | -8.00% |
| 2006 | $71.08M | $99.03M | +$27.95M | +39.32% | +39.32% |
| 2005 | $76.54M | $71.08M | $-5.46M | -7.14% | -7.14% |
| 2004 | $59.28M | $76.54M | +$17.26M | +29.11% | +29.11% |
| 2003 | $35.64M | $59.28M | +$23.64M | +66.34% | +66.34% |
| 2002 | $29.52M | $35.64M | +$6.12M | +20.73% | +20.73% |
| 2001 | $20.27M | $29.52M | +$9.24M | +45.60% | +45.60% |
| 2000 | $18.20M | $20.27M | +$2.08M | +11.40% | +11.40% |
| 1999 | $6.80M | $18.20M | +$11.40M | +167.65% | +167.65% |
| 1998 | $9.50M | $6.80M | $-2.70M | -28.42% | -28.42% |
| 1997 | $3.50M | $9.50M | +$6.00M | +171.43% | +171.43% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q3 2026 | $554.13M | +63.1% | -4.2% |
| Q2 2025 | $339.75M | -25.7% | +10.1% |
| Q1 2025 | $457.32M | -15.1% | +40.5% |
| Q4 2025 | $538.77M | -6.9% | +22.4% |
| Q3 2025 | $578.66M | +87.5% | +43.9% |
| Q2 2024 | $308.62M | -5.2% | +13.1% |
| Q1 2024 | $325.54M | -26.0% | +13.7% |
| Q4 2024 | $440.11M | +9.5% | +85.4% |
| Q3 2024 | $402.03M | +47.4% | +42.3% |
| Q2 2023 | $272.83M | -4.7% | +112.1% |
| Q1 2023 | $286.28M | +20.6% | +541.0% |
| Q4 2023 | $237.44M | -16.0% | +198.7% |
| Q3 2023 | $282.56M | +119.7% | +140.6% |
| Q2 2022 | $128.64M | +188.0% | -41.5% |
| Q1 2022 | $44.66M | -43.8% | — |
| Q4 2022 | $79.49M | -32.3% | -64.9% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael J. Farrell